Immunokind A tablets

Land: Armenien

Sprache: Englisch

Quelle: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Wirkstoff:

calcium carbonicum Hahnemanni D6, calcium fluoratum D6, calcium phosphoricum D6, sulfur jodatum D12

Verfügbar ab:

Dr. Gustav Klein GmbH & Co. KG

ATC-Code:

առկա չէ (L03A)

INN (Internationale Bezeichnung):

calcium carbonicum Hahnemanni D6, calcium fluoratum D6, calcium phosphoricum D6, sulfur jodatum D12

Dosierung:

20mg+ 20mg+ 20mg+ 20mg

Darreichungsform:

tablets

Einheiten im Paket:

(150) in glass container

Verschreibungstyp:

OTC

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2021-04-28

Fachinformation

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
IMMUNOKIND tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 tablet (100 mg) contains:
Active substances:
Calcium carbonicum Hahnemanni D6
20,00 mg
Calcium fluoratum D6
20,00 mg
Calcium phosphoricum D6
20,00 mg
Sulfur jodatum D12
20,00 mg
Excipient with known effect: lactose monohydrate (used as carrier for
the homeopathic triturations)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet. White to almost white, biplane tablet with facet.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
To increase organism’s resistance and for prophylaxis of frequent
and recurrent infectious diseases of
the upper respiratory tract in infants and children of early age.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Children up to 6 years of age: 1 tablet is administered 3 times per
day.
Method of administration
Tablets should be allowed to dissolve slowly in the mouth. If
necessary, tablets can be dissolved in a
little bit of water.
An interval of at least half an hour to meals should be kept.
4.3
CONTRAINDICATIONS
Hypersensitivity to one of the active substances or to any of the
excipients, listed in section 6.1.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
This medicinal product contains lactose. Patients with rare hereditary
problems of galactose
intolerance, the Lapp lactase deficiency or glucose-galactose
malabsorption should not take this
medicinal product.
A reassessment of the therapy is necessary
- if the child is poorly responding to IMMUNOKIND,
- if additional complaints arise.
2
Parents are advised to consult a doctor if their child is suffering
from a thyroid disease before starting
the treatment with IMMUNOKIND.
Parents are advised not to use IMMUNOKIND for long-term treatment
without consultation with a
doctor.
4.5
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
Interactions with other medicinal products have not been observed. The
use of this homeopathic
medicinal product does not ex